Explore

WHO - SMUN 2025

Committee: World Health Organization

Agenda: Tackling Antimicrobial Resistance (AMR) in Global Health

Sponsors: Republic of Tajikistan, The Republic of Chad, The Portuguese Republic, Federal Republic of Germany

Signatories: Kingdom of Saudi Arabia, Dominion of Canada, The Republic of Vanuatu, The Federative Republic of Brazil, The French Republic, United Kingdom of Great Britain and Northern Ireland

The World Health Organization,

Recognizing the urgent global threat of antimicrobial resistance (AMR) and its disproportionate burden on low and middle-income countries (LMICs),

Acknowledging lessons from the COVID-19 pandemic, which demonstrated that international collaboration in healthcare infrastructure benefits all nations,

Recalling WHO guidance on research, surveillance, and equitable access to antimicrobials,

Emphasizing the importance of sustainable, open-access health innovations tailored to LMICs,

Affirming that the return on investments in global health lies in disease eradication and population health, rather than profit,

Encouraging voluntary intellectual property waivers for AMR therapies to ensure equitable access for LMICs, building on the TRIPS waiver precedent from COVID-19 vaccines,

Noting the necessity of political engagement and cross-border coordination to implement AMR mitigation strategies effectively,

1. Establishes the WHO Global AMR Innovation Consortium (GAIC);

i) Provides LMIC-led research grants for novel antimicrobial and bacteriophage therapies

ii) Implements an open-access digital platform for all Member States to share AMR research and outbreak data

2. Launches the Regional AMR Clinical Trials Network;

i) Supports multi-country trials coordinated by LMIC medical institutions;

ii) Provides WHO-endorsed protocols and ethical oversight for rapid innovation;

iii) Ensures local capacity-building and training for laboratory personnel;

3. Creates the Global Health Equity Fund for AMR Innovation;

i) Establishes a collaborative AMR fund in which contributions from Member States are proportional to national healthcare capacity, while LMICs contribute regional expertise and infrastructure support;

ii) Incentivizes technology transfer for local antimicrobial production;

iii) Links funding to collaborative participation in regional research hubs;

iv) Tiered contributions: 0.3% GDP (High-Income), 0.1% (Mid-Income), non-monetary LMIC contributions (e.g., data/labour);

4. Promotes equitable access to AMR interventions based on medical need;

i) Supports voluntary intellectual property waivers for essential antimicrobials;

ii) Implements training programs for LMIC healthcare providers in proper antimicrobial stewardship;

5. Establishes the Rapid AMR Response Protocol (RARP) and the AMR Contribution Index (ACI);

i) Mandates WHO review of emergent treatments within 7 days;

ii) Authorizes emergency local production in LMIC facilities;

iii) Prioritizes interventions in regions with high AMR prevalence;

iv) Tracking financial/data compliance and antibiotic reduction targets;

v) Awarding OPB priority access and fast-tracked licensing to high-performing states;

6. Introduces the One Health Surveillance Dashboard;

i) Integrates human, animal, and environmental AMR data in real-time;

ii) Provides automated alerts for outbreak hotspots;

iii) Requires transparent reporting to WHO, with technical support for LMICs;

7. Deploys AI-driven outbreak prediction and monitoring systems;

i) Focuses on conflict-affected areas and remote regions;

ii) Uses predictive analytics to optimize resource allocation;

9. Establishes Health Neutrality Zones (HNZs) in conflict-affected areas, defined as demilitarized spaces where:

Medical facilities and personnel are protected from attacks under international law;

Safe corridors allow for delivery of aid and evacuation of patients, coordinated by neutral actors like the ICRC;

Mobile clinics and monitoring tools track disease outbreaks and access to care;

Local health workers receive support and training to ensure continuity of services.

10 Mandates reduction of antibiotics in healthy livestock through phased regulation and farmer education programs;

i) Supports the ban of antibiotics in livestock and aquaculture as a growth promoter or preventive measure;

ii) Believes that antibiotics should only be administered under veterinary prescription, and only when no alternative treatments are available for sick livestock and agriculture;

iii) Calls for increased global investment in research and development of new antibiotics, vaccines, rapid diagnostic tools, and alternative treatments, with financial support and scientific contributions from the Global Health Equity Fund;

11. Establishes regional AMR leadership hubs managed by LMICs to coordinate research, training, and emergency responses;

i) Guarantees that LMICs retain ownership over data collected within their borders;

ii) Mandates that all data shared to WHO platforms must include provisions for reciprocal benefits;

iii) Requires that technology transfer agreements between high-income and low-income countries include clauses on capacity-building, co-authorship in research, and affordable access;

iv) Creates a transparent WHO-monitored registry of AMR-related data-sharing and tech-transfer agreements, publicly accessible to all Member States.

12. Establishes the One Health AMR Surveillance Network (OHSN);

i) Supports the deployment of Portugal’s wastewater AI to conflict zones (Chad), mountainous regions (Tajikistan), and SIDS;

ii) Proposes the integration of FAO animal health data and UNEP environmental monitoring;

13. Creates the Open Phage Bank (OPB under WHO management:

i) Uses Tajikistan’s sewage surveillance data for phage discovery;

ii) Grants royalty-free access to LMICs;

iii) Develops rapid phage-based diagnostics;

14. Encourages community engagement campaigns to promote responsible antimicrobial use, including mobile health education programs;

15. Requests contributions to international phage genome and microbial libraries to expand therapeutic options;

16. Supports cross-border collaborative AMR research programs for training, data sharing, and innovation;

17. Reinforces political engagement and international coordination to implement AMR strategies effectively;

18. Highlights that investments in LMIC AMR infrastructure strengthen global health security and provide universal returns, not profit, reflecting lessons learned from COVID-19;

19. Encourages inclusion to have education systems for doctors, high schoolers, and more to have AMR education;

20. Suspends patent rights for non-contributing states;

21. Funds LMIC vaccine production facilities;

22. Reduces patent protections for states in ACI bottom quartile;

23. Recognizes that some countries lack sufficient healthcare infrastructure, the WHO, global NGOs, and developed countries will fund the deployment of mobile clinics and volunteer doctors in regions;

i) Guarantees free or heavily subsidized healthcare for populations below the poverty line;

24. Establishes data collection systems and surveillance networks;

i) Create a global data collection relating to the cases of AMR, deaths from AMR, and results from clinical trials related to the treatments for AMR. Data will also include vaccination rates across various vaccines;

ii) Establishes regional surveillance hubs that combine data from multiple districts by analysing local outbreaks and sending real-time alerts to neighbouring regions. A national and international health network integration will also be created and merged with the WHO;

iii) Uploading all collected data to WHO for the training of AI networks used in data collection and analysis;

25. Encourages Member States to strengthen cooperation between the human health, animal health, and environmental sectors through the One Health approach to reduce misuse of antimicrobials.

26. Invites the creation of training and capacity-building programs for healthcare workers, veterinarians, and pharmacists on antimicrobial stewardship.

27. Proposes the restriction of the Use of Global Health Funds for Peaceful Purposes Only;

i) Allocates all funding for healthcare, AMR reduction, and medical infrastructure must be ring-fenced and strictly prohibited from being diverted to war or military purposes.

ii) Proposes severe penalties, including suspension of international aid and mandatory repayment of funds for countries found guilty of misusing health funds for war-related expenditure will face;

iii) Monitors a WHO-supervised audit system to ensure compliance, with transparent reports published for accountability;

28. Encourages countries to adopt vaccine programs and biosecurity measures in farms to reduce the reliance on antibiotics;

i) Provides technical and financial assistance to farmers in developing countries to transition to sustainable livestock and aquaculture practices;

29. Tightens guidelines on Prescription of Antibiotics;

i) Proposes that antibiotic prescription should follow internationally recognised protocols, to be adapted by each country’s Ministry of Health;

ii) Undergoes mandatory refresher training programs every 2–3 years on AMR and safe antibiotic prescribing for physicians;

iii) Introduces a red flagging system to detect over-prescribing patterns by doctors and pharmacies, with penalties for repeated violations;

30. Requires legislation related to the vaccination, increasing access to vaccination through additional funding and environmental monitoring regulations;

i) Calls upon international organizations, NGOs, and donor countries to collaborate with national governments to ensure equitable vaccine distribution and strengthen immunization infrastructure worldwide;

ii) Encourages member states that have not yet implemented mandatory childhood vaccination policies to draft and adopt legislation ensuring the protection of children against preventable diseases;

iii) Mandates daily checks of water and soil quality in both rural and urban regions, with results published in the Global Data System for transparency;

iv) Enforces of strict environmental regulations to curb industrial pollution, ensuring accountability and compliance across sectors;

v) Supports integration of collected data with WHO frameworks to guide global and local health policies;

31. Improves Living Conditions to Prevent Infections;

i) Prioritizes governments’ basic sanitation infrastructure (clean water access, sewage systems, and waste management) to reduce infection rates;

ii) Supports housing improvements (ventilation, crowding reduction, pest control) by national development funds and international aid;

iii) Encourages the development of Nutritional programs, including food fortification and school meals, which will be expanded to strengthen immune systems and reduce reliance on antibiotics;

32. Recommends the World Health Organization (WHO), in collaboration with the UN Environment Programme (UNEP), to establish global standards for monitoring and managing pharmaceutical waste from antibiotic manufacturing and disposal to prevent environmental contamination;

33. Promotes Public Awareness Campaigns, Strengthening Medical Education and Volunteer Programs;

i) Community-level public awareness campaigns will be launched through schools, local leaders, and health workers to ensure grassroots understanding of hygiene, sanitation, and responsible antibiotic use;

ii) Incorporates governments, in collaboration with WHO and UNESCO, should incorporate modules on Antimicrobial Resistance (AMR), hygiene practices, and rational antibiotic use into school, college, and university syllabi, ensuring that young generations grow up aware of the risks of misuse;

iii) Establishes a “Global Health Volunteer Corps”, where graduates from top international universities in medicine, public health, and biotechnology can volunteer in low-income countries, particularly in Africa and South Asia. These volunteers would train local healthcare staff, conduct awareness workshops, and assist in data collection for national AMR surveillance systems;

iv) Collaborates with Religious leaders and Community elders who are highly respected voices can educate on the misuse of antibiotics and promote responsible antibiotic use as a moral and religious duty, discouraging practices like self-medication, including the use of AMR drugs, discouraging overuse in animals, and sharing prescriptions;

v) Supports emphasis on low-literacy-friendly methods: posters, radio campaigns, folk theatre, and mobile apps for youth for regions with a very low literacy rate;

34. Calls for the establishment of a dedicated Global Vaccine Initiative for AMR, to be hosted by the WHO, with the mandate to accelerate the research, development, and manufacturing of vaccines against priority pathogens, particularly those with high rates of antimicrobial resistance;

i) Encourages Member States and private sector partners to increase financial investment in "push" and "pull" incentives—such as grants, prizes, and market-entry rewards—for the development of new AMR-focused vaccines;

ii) Urges the WHO to work with Member States to develop a framework for equitable access and tiered pricing for all new AMR-related vaccines, ensuring they are affordable and made available to low-resource settings as a global public good

iii) Recommends that Member States integrate the use of both existing and new AMR-focused vaccines into their national immunization programs as a core strategy for reducing antibiotic use and mitigating the spread of resistant infections;

35. Recommends the World Health Organization (WHO), in collaboration with the UN Environment Programme (UNEP), to establish global standards for monitoring and managing pharmaceutical waste from antibiotic manufacturing and disposal to prevent environmental contamination;

36. Encourages Member States to implement national regulations and incentives for pharmaceutical companies to adopt closed-loop systems and best practices that minimize antibiotic discharge into the environment;

37. Calls upon Member States to invest in and upgrade national wastewater treatment facilities to better filter and remove antibiotic residues from water systems before they are released into the environment.

Want to print your doc?
This is not the way.

Try clicking the ··· in the right corner or using a keyboard shortcut (

CtrlP

) instead.